Two recent studies found that S- and RBD-specific immunoglobulin G (IgG) antibodies in patients with COVID-19 have lower levels of fucosylation within their Fc domains 26,27 a phenotype linked to higher affinity for FcRIIIa, an activating Fc receptor (FcR) that mediates antibody-dependent cellular cytotoxicity
At our clinic, the patients who respond best to BPC-157 for gut indications fall into three groups
Side effects include, external vomiting, fatigue and an inflamed pancreas
Most patients use tirzepatide actively for 12 to 24 months, then either maintain on a lower dose or discontinue under medical supervision
While not marketed as a therapeutic agent, tributyrin reflects an interest in maintaining microbial metabolite diversity as part of whole-system gut balance
Molecular Approach and Future Perspectives